RADIOPHARM THERANOSTICS ORD
Radiopharm Theranostics Granted Ethics Approval for RAD402 Phase 1 Trial to Treat Advanced Prostate Cancer
Radiopharm Theranostics (ASX: RAD) has received Bellberry human research ethics committee approval in Australia for a Phase 1 first in-human clinical trial of RAD402 for the treatment of metastatic or locally-advanced prostate cancer.
Starpharma and Radiopharm Theranostics Partner to Develop Novel Radiotherapy Asset
Starpharma Holdings (ASX: SPL) has entered into a research and option partnership with Radiopharm Theranostics (ASX: RAD) to develop and manufacture a dendrimer drug conjugate incorporating a radiopharmaceutical molecule to target certain cancers. The partnership, which follows six months of preliminary research under Starpharma’s Star Navigator drug development program, will see Radiopharm pay Starpharma a $500,000 for an […]
Radiopharm Theranostics Receives FDA Investigational New Drug Clearance for RV-01 Cancer Therapy
Radiopharm Theranostics (ASX: RAD) has received investigational new drug clearance from the US Food and Drug Administration (FDA) for therapeutic candidate Betabart (RV-01). RV-01 targets the B7H3 immune checkpoint molecule that plays a role in cancer development and progression. The FDA clearance will now allow the company to initiate a first-in-human Phase 1 clinical trial […]
Radiopharm Theranostics earns FDA approval for brain metastasis imaging agent RAD 101
Clinical-stage biopharmaceutical company Radiopharm Theranostics (ASX: RAD) has received clearance from the US Food and Drug Administration (FDA) for an investigational new drug (IND) application relating to F18-Pivalate (RAD 101). RAD 101 is a proprietary imaging agent currently under clinical investigation for the detection and characterisation of brain metastases. Labelled with the radioisotope F18, pivalate […]